Jubilant Therapeutics Inc.

Jan 08, 2024

JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis

Feb 05, 2021

Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors

Jan 15, 2021

Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19

Dec 07, 2020

Jubilant Therapeutics announces Efficacy and Biomarker Data at 62nd ASH Annual Meeting for its Novel Dual LSD1-HDAC6 Inhibitor for the Treatment of Hematological Cancers

Nov 04, 2020

Jubilant Therapeutics to Participate in Upcoming Investor Conferences

Oct 20, 2020

Jubilant Therapeutics Strengthens Scientific Advisory Board